Comparative Pharmacology
Head-to-head clinical analysis: FLUOTHANE versus KETAMINE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOTHANE versus KETAMINE HCL.
FLUOTHANE vs KETAMINE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.
None Documented
None Documented
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Terminal elimination half-life: 2–4 hours (alpha: 10–15 min, beta: 2.5–4 hr); prolonged in hepatic impairment and with repeated dosing (up to 12–24 hr for active metabolite norketamine).
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Renal: 90% as metabolites (norketamine, dehydronorketamine, hydroxylated derivatives) and 4% unchanged; biliary/fecal: 3%; minor pulmonary exhalation.
Category C
Category C
General Anesthetic
General Anesthetic